Literature DB >> 30030540

In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Benjamin Vidal1, Sylvain Fieux1, Jérôme Redouté2, Marjorie Villien2, Frédéric Bonnefoi2, Didier Le Bars2,3, Adrian Newman-Tancredi4, Nicolas Costes2, Luc Zimmer5,6,7.   

Abstract

In neuropharmacology, the recent concept of 'biased agonism' denotes the capacity of certain agonists to target-specific intracellular pathways of a given receptor in specific brain areas. In the context of serotonin pharmacotherapy, 5-HT1A receptor-biased agonists could be of great interest in several neuropsychiatric disorders. The aim of this study was to determine whether biased agonists could be differentiated in terms of regional targeting by use of simultaneous functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) brain imaging. We compared two 5-HT1A-biased agonists, NLX-112 and NLX-101, injected at three different doses in anaesthetised cats (n = 4). PET imaging was acquired for 90 min after bolus administration followed by constant infusion of the 5-HT1A radiotracer, [18F]MPPF. Drug occupancy was evaluated after injection at  50 min and BOLD fMRI was simultaneously acquired to evaluate subsequent brain activation patterns. 5-HT1A receptor occupancy was found to be dose-dependent for both agonists, but differed in magnitude and spatial distribution at equal doses with distinct BOLD patterns. Functional connectivity, as measured by BOLD signal temporal correlations between regions, was also differently modified by NLX-112 or NLX-101. Voxel-based correlation analyses between PET and fMRI suggested that NLX-112 stimulates both 5-HT1A autoreceptors and post-synaptic receptors, whereas NLX-101 preferentially stimulates post-synaptic cortical receptors. In cingulate cortex, the agonists induced opposite BOLD signal changes in response to receptor occupancy. These data constitute the first simultaneous exploration of 5-HT1A occupancy and its consequences in terms of brain activation, and demonstrates differential signalling by two 5-HT1A-biased agonists. Combined PET/fMRI represents a powerful tool in neuropharmacology, and opens new ways to address the concept of biased agonism by translational approaches.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30030540      PMCID: PMC6135772          DOI: 10.1038/s41386-018-0145-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  45 in total

1.  In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.

Authors:  Laia Lladó-Pelfort; Marie-Bernadette Assié; Adrian Newman-Tancredi; Francesc Artigas; Pau Celada
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

2.  A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment.

Authors:  Nicolas Aznavour; Latifa Rbah; Mustapha Riad; Anthonin Reilhac; Nicolas Costes; Laurent Descarries; Luc Zimmer
Journal:  Neuroimage       Date:  2006-09-25       Impact factor: 6.556

3.  High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity.

Authors:  Jean Louis Maurel; Jean-Marie Autin; Philippe Funes; Adrian Newman-Tancredi; Francis Colpaert; Bernard Vacher
Journal:  J Med Chem       Date:  2007-09-06       Impact factor: 7.446

4.  Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study.

Authors:  Jaroslava Buritova; Geraldine Berrichon; Claudie Cathala; Francis Colpaert; Didier Cussac
Journal:  Neuropharmacology       Date:  2008-09-17       Impact factor: 5.250

5.  F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.

Authors:  Ronan Depoortère; Agnès L Auclair; Laurent Bardin; Francis C Colpaert; Bernard Vacher; Adrian Newman-Tancredi
Journal:  Eur Neuropsychopharmacol       Date:  2010-05-21       Impact factor: 4.600

6.  Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans.

Authors:  D Martinez; D Hwang; O Mawlawi; M Slifstein; J Kent; N Simpson; R V Parsey; T Hashimoto; Y Huang; A Shinn; R Van Heertum; A Abi-Dargham; S Caltabiano; A Malizia; H Cowley; J J Mann; M Laruelle
Journal:  Neuropsychopharmacology       Date:  2001-03       Impact factor: 7.853

Review 7.  Data collection and analysis strategies for phMRI.

Authors:  Joseph B Mandeville; Christina H Liu; Wim Vanduffel; John J A Marota; Bruce G Jenkins
Journal:  Neuropharmacology       Date:  2014-03-05       Impact factor: 5.250

8.  Functional Characterization of 5-HT1B Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR.

Authors:  Hanne D Hansen; Joseph B Mandeville; Christin Y Sander; Jacob M Hooker; Ciprian Catana; Bruce R Rosen; Gitte M Knudsen
Journal:  J Neurosci       Date:  2017-10-02       Impact factor: 6.167

Review 9.  5-HT1A Receptor-Mediated Autoinhibition and the Control of Serotonergic Cell Firing.

Authors:  Rodrigo Andrade; Daniel Huereca; Joseph G Lyons; Elaine M Andrade; Kelly M McGregor
Journal:  ACS Chem Neurosci       Date:  2015-05-26       Impact factor: 4.418

10.  Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.

Authors:  J S Dileep Kumar; Jaya Prabhakaran; Vattoly J Majo; Matthew S Milak; Shu-Chi Hsiung; Hadassah Tamir; Norman R Simpson; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-13       Impact factor: 10.057

View more
  6 in total

Review 1.  Advances in simultaneous PET/MR for imaging neuroreceptor function.

Authors:  Christin Y Sander; Hanne D Hansen; Hsiao-Ying Wey
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-13       Impact factor: 6.200

2.  Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks.

Authors:  Sabina Marciano; Tudor M Ionescu; Ran Sing Saw; Rachel Y Cheong; Deniz Kirik; Andreas Maurer; Bernd J Pichler; Kristina Herfert
Journal:  Proc Natl Acad Sci U S A       Date:  2022-09-26       Impact factor: 12.779

3.  Serodolin, a β-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors.

Authors:  Chayma El Khamlichi; Flora Reverchon; Nadège Hervouet-Coste; Elodie Robin; Nicolas Chopin; Emmanuel Deau; Fahima Madouri; Cyril Guimpied; Cyril Colas; Arnaud Menuet; Asuka Inoue; Andrzej J Bojarski; Gérald Guillaumet; Franck Suzenet; Eric Reiter; Séverine Morisset-Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-20       Impact factor: 12.779

Review 4.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

5.  [18F]F13640, a 5-HT1A Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations.

Authors:  Matthieu Colom; Benjamin Vidal; Sylvain Fieux; Jérôme Redoute; Nicolas Costes; Franck Lavenne; Inés Mérida; Zacharie Irace; Thibaud Iecker; Caroline Bouillot; Thierry Billard; Adrian Newman-Tancredi; Luc Zimmer
Journal:  Front Neurosci       Date:  2021-03-08       Impact factor: 4.677

Review 6.  Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges.

Authors:  Oriane Razakarivony; Adrian Newman-Tancredi; Luc Zimmer
Journal:  Transl Psychiatry       Date:  2021-01-07       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.